Director/Senior Director of Medicinal Chemistry

Executive Assistant to the CEO & CBO and Office Manager

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acrotech Biopharma

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

AiLife Diagnostics

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

Aleo BME

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altavant Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Anagenex

Analytical BioSciences

Andes

Angiocrine Bioscience

AnHeart Therapeutics

AnimalBiome

Annexon Biosciences

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aqua Cultured Foods

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Ardra

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.

<p>1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&amp;D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.</p>


Find a biotech startup job.